These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8294674)

  • 21. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis.
    Wallach JD; Egilman AC; Ross JS; Woloshin S; Schwartz LM
    J Gen Intern Med; 2019 Apr; 34(4):492-495. PubMed ID: 30543020
    [No Abstract]   [Full Text] [Related]  

  • 22. "Safer, but not safe enough".
    Crombie HD
    Conn Med; 2006; 70(10):645. PubMed ID: 17190395
    [No Abstract]   [Full Text] [Related]  

  • 23. How the US drug safety system should be changed.
    Strom BL
    JAMA; 2006 May; 295(17):2072-5. PubMed ID: 16670415
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA not NIH can speed new drugs.
    Miller HI
    Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
    [No Abstract]   [Full Text] [Related]  

  • 25. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 26. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

  • 27. Food and Drug Administration, partner in drug development.
    Yates JW
    CA Cancer J Clin; 2006; 56(6):321-2. PubMed ID: 17135690
    [No Abstract]   [Full Text] [Related]  

  • 28. The US Food and Drug Administration's Model-Informed Drug Development Paired Meeting Pilot Program: Early Experience and Impact.
    Madabushi R; Benjamin JM; Grewal R; Pacanowski MA; Strauss DG; Wang Y; Zhu H; Zineh I
    Clin Pharmacol Ther; 2019 Jul; 106(1):74-78. PubMed ID: 31081932
    [No Abstract]   [Full Text] [Related]  

  • 29. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 30. PDUFA reauthorization--drug safety's golden moment of opportunity?
    Hennessy S; Strom BL
    N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
    [No Abstract]   [Full Text] [Related]  

  • 31. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 32. A Food and Drug Administration primer.
    Simon LS
    Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403
    [No Abstract]   [Full Text] [Related]  

  • 33. FDA restructures new product review centers.
    Bouchie A
    Nat Biotechnol; 2002 Oct; 20(10):960. PubMed ID: 12355100
    [No Abstract]   [Full Text] [Related]  

  • 34. Reform of drug regulation--beyond an independent drug-safety board.
    Ray WA; Stein CM
    N Engl J Med; 2006 Jan; 354(2):194-201. PubMed ID: 16407517
    [No Abstract]   [Full Text] [Related]  

  • 35. How are drugs approved? Part 1: the evolution of the Food and Drug Administration.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2008 Jan; 46(1):15-9. PubMed ID: 18251347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 37. Lessons learned from the COX-2 advisory hearings.
    Somberg J
    Am J Ther; 2005; 12(2):105. PubMed ID: 15767826
    [No Abstract]   [Full Text] [Related]  

  • 38. What ails the FDA?
    Jenny-Avital ER
    N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
    [No Abstract]   [Full Text] [Related]  

  • 39. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 40. Lawsuit seeks access to data from hepatitis C drug trial.
    McCarthy M
    BMJ; 2015 Jun; 350():h3564. PubMed ID: 26126508
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.